Global Anti-CD20 Monoclonal Antibodies Market to Reach US$12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Anti-CD20 Monoclonal Antibodies market. The global market for Anti-CD20 monoclonal antibodies is projected to exceed US$12 billion by the year 2015. Rising incidence and prevalence of autoimmune diseases and hematological malignancies, the major targeted indications of CD20 mAbs, and the existence of high unmet medical needs, are the factors driving growth in the market.

CD20 Monoclonal Antibodies: A Global Strategic Business Report

The antibody therapeutics sector is presently in a dynamic state of growth in the global pharmaceutical industry. In recent years, antibody therapeutics has transformed the treatment of inflammatory diseases and cancer. The advent of Rituximab in 1997 not only validated the CD20-targeting phenomenon in improving overall response and providing benefits in the treatment of B-cell malignancies, but also revolutionized the area of cancer treatment.

Several patients worldwide continue to benefit from Rituxan. However, a significant number of patients also exist who have developed resistance or are refractory to the drug. In addition, there are issues regarding the adverse events pertaining to infusion of the drug. As a result, the need for new and more effective drugs continue to exist. Several companies have, ever since, embarked on the discovery and development of novel CD20 mAbs that paved way for the discovery of new drugs with novel action mechanisms for more efficient treatment of these B-cell malignancies. In addition to huge unmet medical needs, growth in the CD-20 market would be spurred by rising incidence and prevalence of conditions such as non-Hodgkin’s Lymphoma, Rheumatoid arthritis and chronic lymphocytic leukemia, which represent the major target indications for CD20 monoclonal antibodies.

The United States represents the single largest market for CD20 monoclonal antibodies, as stated by the new market research report on Anti-CD20 Monoclonal Antibodies. Hematological malignancies such as non-Hodgkin’s Lymphoma continue to be a major indication targeted by a majority of drugs in development. Other major indications includes Rheumatoid Arthritis and Chronic Lymphocytic Leukemia.

Key players profiled in the report include Genentech Inc., F. Hoffmann-La Roche Ltd., Biogen Idec Inc., GlaxoSmithKline, Genmab A/S, Bayer Schering Pharma AG, Spectrum Pharmaceuticals Inc., Pfizer Inc., Eli Lilly and Company, Trubion Pharmaceuticals Inc., and others.

The report titled “CD20 Monoclonal Antibodies: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the global CD20 Monoclonal Antibodies market, presently marketed antibodies, pipeline antibodies, key market trends, drug approvals, recent corporate initiatives, and focus on major and niche market participants. The study analyzes market data and analytics in terms of value sales for the US and Rest of World markets.

For more details about this market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website